Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry.
Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry.
复制标题
DOI：
10.5114/aic.2018.76406
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Buszman PE
中科院分区：
文献类型：
--
作者：
Orlik B;Milewski K;Derbisz K;Jelonek M;Chrząszcz P;Beil S;Młodziankowski A;Picheta W;Buszman PP;Buszman PE
大多数与生物可吸收血管支架（BVS）技术相关的临床试验仅限于高度选择的患者人群。评价Absorb依维莫司洗脱BVS与依维莫司洗脱金属XIENCE V支架在常规临床实践中的早期和长期临床结局。这是一项多中心、回顾性倾向评分匹配的比较研究，包括76例接受裸金属支架（BMS）治疗的患者和501例接受XIENCE支架治疗的患者。研究中纳入的患者有稳定型和不稳定型心绞痛以及两种类型的心肌梗死（STEMI和NSTEMI）作为介入治疗的适应症，并且自体冠状动脉中至少有一处显著的原发病变。主要终点是主要不良心血管事件（MACE），定义为死亡、心肌梗死（MI）或靶血管血运重建（TVR）。两组的中位随访时间均为400天。在患者基线特征的倾向评分匹配后，BVS组中只有较高的预扩张率、主要治疗的左前降支（LAD）和较低的使用支架数量仍具有统计学显著性。调整后，治疗的病变类型无差异。BVS组和药物洗脱支架（DES）组的MACE发生率无差异（分别为7.2% vs. 11.15%; p = 0.17）。两组的TVR均为2.9%。除围手术期外，BVS组无死亡或MI。两个研究组均无支架内血栓形成。在整个长期随访的常规临床实践中，成功植入Absorb BVS的患者的临床结局与植入Xience支架的患者无差异。需要更长时间的随访数据来确定这些发现是否会持续超过一年。
Most clinical trials related to bioresorbable vascular scaffold (BVS) technology are limited to a highly selected patient population. To evaluate early and long-term clinical outcomes of the Absorb everolimus-eluting BVS compared to the everolimus-eluting metallic XIENCE V stent in routine clinical practice. This is a multicenter, retrospective propensity score-matched comparative study, comprising 76 patients treated with a bare metal stents (BMS) and 501 with a XIENCE stent. Patients included in the study had stable and unstable angina and both types of myocardial infarction (STEMI and NSTEMI) as an indication for intervention and at least one significant de novo lesion in native coronary arteries. The primary endpoint was major adverse cardiovascular event (MACE), defined as death, myocardial infarction (MI), or target vessel revascularization (TVR). Median follow-up was 400 days in both groups. After propensity score matching for patient baseline characteristics, only higher rate of predilatation, predominantly treated left anterior descending artery (LAD) and lower number of used stents in the BVS group remained statistically significant. After adjustment there was no difference in type of treated lesions. The MACE rate did not differ between BVS and drug-eluting stents (DES) groups (7.2% vs. 11.15%, respectively; p = 0.17). The TVR was 2.9% in both groups. Except in the periprocedural period, there were no deaths or MI in the BVS group. There was no stent thrombosis in either studied group. In routine clinical practice throughout long-term follow-up, clinical outcomes of patients who successfully received the Absorb BVS did not differ from those of patients who received the Xience stent. Longer follow-up data are required to determine whether these findings will persist beyond one year.
登录
查看更多内容
DOI：
10.5114/pwki.2014.46940
发表时间：
2014
期刊：
Postepy w kardiologii interwencyjnej = Advances in interventional cardiology
影响因子：
--
作者：
Lesiak M;Araszkiewicz A
通讯作者：
Araszkiewicz A
影响因子：
158.5
作者：
Ellis, Stephen G.;Kereiakes, Dean J.;Stone, Gregg W.
通讯作者：
Stone, Gregg W.
影响因子：
6.2
作者：
Capodanno, Davide;Gori, Tommaso;Tamburino, Corrado
通讯作者：
Tamburino, Corrado
影响因子：
39.3
作者：
Kimura, Takeshi;Kozuma, Ken;Stone, Gregg W.
通讯作者：
Stone, Gregg W.
DOI：
10.1161/circinterventions.115.002427
发表时间：
2015-06-01
影响因子：
5.6
作者：
Koppara, Tobias;Cheng, Qi;Joner, Michael
通讯作者：
Joner, Michael